Article Text

PDF
13 Oral P2Y12 inhibitor therapy in heat-PPCI: results of a pre-specified sub-study examining early effects on platelet aggregation and clinical events
  1. Adeel Shahzad1,
  2. Vikram Khanna2,3,
  3. Ian Kemp1,
  4. Christine Mars1,
  5. Rob Cooper1,
  6. Claire Roome1,
  7. Keith Wilson1,
  8. Nick Curzen2,3,
  9. Rod Stables1
  1. 1Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital NHS Trust, Liverpool
  2. 2University Hospital Southampton NHS Foundation Trust
  3. 3School of Medicine, University of Southampton, UK

Abstract

Background HEAT-PPCI compared bivalirudin and heparin in patients undergoing primary percutaneous coronary intervention. All patients received pre-procedural oral anti-platelet therapy, initially prasugrel (Pr) with some use of clopidogrel (C). Later, routine therapy switched to ticagrelor (T) (Figure 1a).

Methods During working hours, Multiple Electrode Aggregometry (MEA) was used to assess ADP-induced platelet aggregation at the end of the index procedure.

The effect of P2Y12 agents on MACE and major bleeding outcomes was assessed in all patients. Multiple logistic regression was used to adjust for baseline differences.

Results With MEA data from 469 patients, Pr therapy resulted in greater suppression of platelet aggregation - 1b.

In the entire study population Pr therapy was associated with reduced MACE. After adjustment there were no significant differences in the rates of MACE or major bleeding - 1c.

Conclusion Patients who received Pr (rather than C or T) had greater suppression of ADP-induced aggregation at the end of the procedure. After adjusting for baseline characteristics, these results were not associated with significant differences in clinical events.

Abstract 13 Figure 1

A. Evolution of P2Y12 inhibitor use over time. B. Comparison of suppression of ADP-induced platelet aggregation. C. Primary efficacy outcome (MACE) at 28 days.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.